(Q82079038)

English

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma

scientific article published on 25 September 2008

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Clinical outcome of combined immunotherapy with interferon-alpha and low-dose interleukine-2 for Japanese patients with metastatic renal cell carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

1 reference

based on heuristic

inferred from title

renal cell carcinoma

1 reference

based on heuristic

inferred from title

metastatic renal cell carcinoma

1 reference

based on heuristic

inferred from title

author name string

Hideaki Miyake

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Toshifumi Kurahashi

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Atsushi Takenaka

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Taka-aki Inoue

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Masato Fujisawa

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

publication date

25 September 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Urologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

27

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

598-603

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Present strategies in the treatment of metastatic renal cell carcinoma: an update on molecular targeting agents.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Targeted molecular therapy for renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Phase II study to investigate the efficacy, safety, and pharmacokinetics of sorafenib in Japanese patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Clinical outcome of combined immunotherapy with low-dose interleukin-2 and interferon-alpha for Japanese patients with metastatic renal cell carcinoma who had undergone radical nephrectomy: a preliminary report

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Sunitinib versus interferon alfa in metastatic renal-cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal-cell carcinoma. Groupe Français d'Immunothérapie

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Thirteen-year, long-term efficacy of interferon 2alpha and interleukin 2-based home therapy in patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Immunotherapy with concurrent subcutaneous GM-CSF, low-dose IL-2 and IFN-alpha in patients with progressive metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Long-term immunotherapy with low-dose interleukin-2 and interferon-alpha in the treatment of patients with advanced renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

C-reactive protein: a biomarker of survival in patients with metastatic renal cell carcinoma treated with subcutaneous interleukin-2 based immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2008.07.023

7 January 2021

Identifiers

10.1016/J.UROLONC.2008.07.023

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18818106%20AND%20SRC:MED&resulttype=core&format=json

14 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q82079038&oldid=2235136181"